Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 137 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Low-dose computed tomography Clear all

Conditions: Lung Cancer
Interventions: chest computed tomography scan; Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: 64Cu-LLP2A, PET/MR, Blood samples for serum stability, Blood samples for metabolite analysis, Urine sample, Tumor biopsy, Electrocardiogram, PET/CT; Drug · Device · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy Volunteer, Coronary Arterial Disease, Myocardial Ischemia, Myocardial Infarction
Interventions: 18F-flurpiridaz; Drug
Lead sponsor: Akiva Mintz; Other
Eligibility: 18 Years to 120 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Englewood, New Jersey

Conditions: Lung Cancer, Smoking Cessation, Tobacco Use Cessation
Interventions: Patient Decision Aid, Standard Educational Information, Follow-Up Assessments: Questionnaires; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 55 Years to 77 Years
Enrollment: 516 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Ridgeland, Mississippi

Conditions: Nephrolithiasis, Ureterolithiases
Interventions: Extremely low dose CT; Diagnostic Test
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 4 Years to 20 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cystinuria
Interventions: Alpha lipoic acid, Placebo; Dietary Supplement · Drug
Lead sponsor: Thomas Chi, MD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography; Biological · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Colorectal Cancer, Lung Cancer, Breast Cancer
Interventions: Decision Making Support Tool; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 50 Years to 80 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, aldesleukin, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis; Drug · Biological · Radiation + 2 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Cancer
Interventions: Letter, Community Health Worker Phone Call; Behavioral
Lead sponsor: Anne Conners; Other
Eligibility: 55 Years to 80 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Augusta, Maine

Conditions: Neuroendocrine Tumors
Interventions: PET/CT Imaging, 68Ga-DOTA-JR11, 177Lu-DOTA-JR11; Device · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomography, Stereotactic Body Radiation Therapy; Procedure · Radiation · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Duarte, California

Conditions: Lung Cancer
Interventions: Patient Navigation, Usual Care; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 55 Years to 77 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Shoulder Arthroplasty
Interventions: A low-dose CT scan of the shoulder; Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: High Risk Cancer, Lung Cancer
Interventions: Median LCS; Device
Lead sponsor: Median Technologies; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania • Memphis, Tennessee • Houston, Texas

Conditions: Steatosis of Liver, NASH - Nonalcoholic Steatohepatitis
Interventions: Fibroscan of Liver, Low-dose non-contrast CT; Device · Procedure
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 55 Years to 80 Years
Enrollment: 340 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: PET/CT Imaging
Interventions: PET/CT scan with 13 mCi radiation dose, PET/CT scan with 5 mCi radiation dose, PET/CT scan with 2.5 mCi radiation dose, PET/CT Scan with 6.5 mCi radiation dose, PET/CT Scan with not yet determined radiation dose; Diagnostic Test
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Family History of Lung Cancer
Interventions: CT scan, Sybil; Diagnostic Test · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hodgkin Disease
Interventions: ABVE-PC, DECA; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer, Lung Carcinoma
Interventions: Low-dose Computed Tomography; Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years to 80 Years
Enrollment: 900 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: Morbid Obesity, Respiratory Failure
Interventions: low-dose chest CT scan, insertion of esophageal balloon; Radiation · Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Gastroparesis With Diabetes Mellitus
Interventions: PET/CT Scan with 11C-ER176, Core biopsy of gastric muscle; Drug · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Neoplasms, Lung Cancer
Interventions: Mobile Low-dose Computed Tomography (LDCT) Screening; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 40 Years to 54 Years
Enrollment: 1,160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Nodule Solitary Pulmonary, Non-small Cell Lung Cancer
Interventions: Guardant Health ct-DNA LUNAR assay; Diagnostic Test
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years and older
Enrollment: 1,440 participants
Timeline: 2017 – 2030
U.S. locations: 3
States / cities: San Francisco, California

Search by objective public record fields.

Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease

64Cu-LLP2A for Imaging Multiple Myeloma

Ultralow Dose PET Imaging of 18F-flurpiridaz

PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening

Validation of Low Dose CT for Diagnosis of Urolithiasis

Lipoic Acid Supplement for Cystine Stone

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

Technology-Based Cancer Screening Intervention

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Maine Lung Cancer Coalition: Using CHWs for the Annual Lung Cancer Screening Reminder

Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors

A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab

Patient Navigation for Lung Screening at MGH Community Health Centers

Prospective Low Dose CT for Total Shoulder Arthroplasty/Reverse Shoulder Arthroplasty

Retrospective Clinical Trial Comparing Radiologists' Diagnosis Accuracy in Lung Cancer Screening Population With and Without the Help of an AI/ML Tech-based SaMD

The Liver in the World Trade Center Health Program General Responder Cohort and Controls

Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT

LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol A

Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A

Lung Cancer Screening in High-risk Black Individuals

Comparison of Esophageal Manometry and CT Scan Measurements

PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis

Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

Biomarkers for Risk Stratification in Lung Cancer